|Healthcare review: Endocyte, Chelsea Therapeutics International, Genomic Health, Viropharma Inc, Orexigen Therapeutics|
|By Staff and Wire Reports|
|Wednesday, 27 March 2013 15:34|
Following are notable movers at mid day on Wednesday:-
Endocyte, Inc. (NASDAQ:ECYT) stock gained 6.79% to $11.48 after Robert W. Baird upgraded shares of ECYT from a neutral rating to an outperform rating in a research note issued to investors on Mar. 25. The firm currently has $13.00 target price on the stock, up from their previous target price of $9.00.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) shares increased 9.15% to $2.02. The Company, on Mar. 7, reported financial results for the fourth quarter and full year ended December 31, 2012. For the quarter ended December 31, 2012, CHTP reported a net loss of $2.2 million or ($0.03) per share versus a net loss of $12.5 million or ($0.20) per share for the same period in 2011. For the twelve months ended December 31, 2012, Chelsea reported a net loss of $31.7 million or ($0.47) per share compared to a net loss of $50.5 million or ($0.84) per share for the same period in 2011.
Genomic Health, Inc. (NASDAQ:GHDX) stock climbed 6.66% to $28.50 after GHDX’s stock was upgraded by equities research analysts at Leerink Swann from a “market perform” rating to an “outperform” rating in a research note issued to investors on Mar. 27.
Additionally, the company, on Mar. 13, announced positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of loco-regional recurrence (LRR) in node-positive (N+), estrogen receptor (ER) positive patients treated with adjuvant hormonal therapy and chemotherapy.
Viropharma Inc. (NASDAQ:VPHM) shares climbed 4.27% to $24.44 in the early hour. The company, on Feb. 27, reported a fourth-quarter GAAP net loss of $3.9 million or $0.06 per share compared to a GAAP net income of $53.1 million or $0.65 per share in the fourth quarter of 2011. However, on an adjusted basis the company posted a profit of $7.1 million, or $0.10 per share. Meanwhile, net sales fell to $106.49 million for the fourth quarter, from $145.57 million in the same three months of 2011. Analysts expected the company to report earnings of $0.03 per share on revenues of $103.06 million for the quarter.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares gained 3.36% to $5.84. The company, on Mar. 13, posted fourth-quarter net loss of $32.5 million or $0.41 per share, wider than $4.3 million or $0.09 per share in the previous year quarter. Total revenues for the quarter were $857 thousand, flat with last year. Analysts expected the company to report a loss of $0.44 per share on revenues of $910 thousand.